Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:10/20/2009

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the BIOCOM Life Science Investor Conference on Monday, October 26, 2009 at 5:00 p.m. PDT (8:00 p.m. EDT). The conference is being held at the Hyatt Regency La Jolla Hotel in San Diego. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Dr. Worland will also present a Company overview at the 8th Annual BIO Investor Forum on Wednesday, October 28, 2009 at 10:00 a.m. PDT (1:00 p.m. EDT). The conference is being held at the Palace Hotel in San Francisco.

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentation at the BIOCOM Life Science Investor Conference will be available approximately one hour after the live webcast concludes and will be available through November 9, 2009. A replay of the presentation at the 8th Annual BIO Investor Forum will be available approximately one hour after the live webcast concludes and will be available through November 11, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is deve
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: ... on significant strategic and financial initiatives at its ... Conference is hosted by Peter H. Soderberg, president ... on the following topics: ,, Status of ... development and financial updates Smart technologies that ...
(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...
(Date:12/15/2009)... SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... AMLN ), Eli Lilly and Company (NYSE: ... ALKS ) today announced positive results from ... investigational diabetes therapy, to BYETTA® (exenatide) injection taken ... After 24 weeks of treatment, patients taking exenatide ...
Breaking Medicine Technology:Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 1First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 2First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 3First Defense Nasal Screen Comp Releases New Protection Product Just in Time for Pandemic Flu Season 55643 4Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 1Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 2Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 55641 3Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2
... U.S.-based subsidiary of,Pharmexa A/S, presents selected data ... Influenza Conference entitled, "Options for,the Control of ... The,data show that a "universal" vaccine designed ... mice against,lethal experimental influenza virus challenge. , ...
... SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, ... non-profit,pharmaceutical company, today announced that Phase 3 research,related ... (Paromomycin), was published in the current issue of ... trial shows,that the medicine paromomycin is safe, effective, ...
Other Medicine Technology:Pharmexa A/S (DK) - Pharmexa presents data from influenza program 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4
(Date:12/15/2009)... require that certain businesses with large areas where people gather, ... available. Fire and rescue personnel agree that for any size ... , ... Issaquah, WA (PRWEB) December ... that certain businesses with large areas where people gather, need ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 "The entire San ... mourns the passing of Sol Price on December 14, ... standards of integrity, loyalty and ethics in his business, ... and thoughtful humanitarian who truly understood the responsibility of ... and his legacy will live on through his countless ...
(Date:12/15/2009)... UT Southwestern Medical Center researchers have provided ... unique observable characteristics seen in patients with an ... reported online and in the December issue of ... suggest that patients with atypical progeroid syndrome ... diagnosed with two similar but more well-defined accelerated ...
(Date:12/14/2009)... and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... Scientists at UC Santa Barbara, in collaboration with scientists at ... the characteristics and key functions of natural red blood cells, ... , , , , ,The primary function of natural red ...
(Date:12/14/2009)... Fla., Dec. 14 Abbott (NYSE: ... definitive agreement to acquire STARLIMS Technologies Ltd. ... of laboratory information management systems, for approximately ... acquisition strengthens Abbott,s competitive position in the ... to help laboratories efficiently store, retrieve and ...
Breaking Medicine News(10 mins):Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4
... controls the rapid production and differentiation of the stem cells that ... open the door to more streamlined treatments for leukemia and other ... , ... (Vocus) April 8, 2009 -- Researchers have identified ...
... IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") participated ... at PLA 301 Hospital in Beijing on April 5, ... and Hong Kong attended the inaugural event that focused ... was opened by Dir Chen Xiaohong, Director of PLA ...
... Leadership Conference on April 24 ALEXANDRIA, Va., April 8 ... president and CEO, joined an invitation-only meeting at the ... appointed Director of the White House Office of Health ... to this important meeting is an indicator of the ...
... AJ,s grocery stores sell limited-edition, reusable grocery totes to ... age-old question of "paper or plastic" by choosing to ... Children,s Hospital. Bashas, Food City and AJ,s grocery stores ... Shamrock Farms on a charitable "green" mission this spring. ...
... drug lowers prostate specific antigen (PSA) levels a ... prostate cancer for whom traditional treatment options have failed. ... Center (MSKCC), is published today in Science ... ., Most men with metastatic prostate cancer eventually build ...
... Cancer Researchers and Updates on Key Discoveries, Plus ... April 8 Internationally renowned physician-scientists will discuss ... US, plus important recent discoveries in translational cancer ... Cancer Research Foundation Clinical Investigator Symposium.The ...
Other Medicine News:Health News:Scientists Identify Key Gene That Protects Against Leukemia 2Health News:Scientists Identify Key Gene That Protects Against Leukemia 3Health News:Scientists Identify Key Gene That Protects Against Leukemia 4Health News:Neurosurgeons from around the world gather at PLA 301 Hospital in China 2Health News:NHPCO President/CEO Meets with Nancy-Ann Min DeParle at White House 2Health News:Hometown Grocer, Local Food Companies Team up to Support Pediatric Patients, Encourage 'Green' Lifestyle 2Health News:Hometown Grocer, Local Food Companies Team up to Support Pediatric Patients, Encourage 'Green' Lifestyle 3Health News:Hometown Grocer, Local Food Companies Team up to Support Pediatric Patients, Encourage 'Green' Lifestyle 4Health News:Drug shows activity in men with advanced prostate cancer 2Health News:Drug shows activity in men with advanced prostate cancer 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: